sb 203580 has been researched along with sesamol in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (sesamol) | Trials (sesamol) | Recent Studies (post-2010) (sesamol) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 247 | 1 | 164 |
| Protein | Taxonomy | sb 203580 (IC50) | sesamol (IC50) |
|---|---|---|---|
| Polyphenol oxidase 2 | Agaricus bisporus | 6.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, CM; Chen, CH; Chen, FY; Chen, WY; Hsu, JF; Lee, AS; Lee, WS; Shen, MY; Sheu, JR; Ting, KH | 1 |
1 other study(ies) available for sb 203580 and sesamol
| Article | Year |
|---|---|
Sesamol reduces the atherogenicity of electronegative L5 LDL in vivo and in vitro.
Topics: Animals; Apoptosis; Atherosclerosis; Benzodioxoles; Blotting, Western; Caspase 3; Cricetinae; Dose-Response Relationship, Drug; Endothelial Cells; Humans; In Vitro Techniques; Lipoproteins, LDL; Male; Molecular Structure; Phenols; Scavenger Receptors, Class E | 2015 |